Risk factors associated with severe and recurrent angioedema: An epidemic linked to ACE‐inhibitors
- 17 June 2014
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 124 (11), 2502-2507
- https://doi.org/10.1002/lary.24777
Abstract
Objectives/Hypothesis To evaluate the etiology and risk factors for severe manifestation and recurrent episodes of angioedema; to evaluate efficacy of short-term and long-term management strategies for angioedema among a high-risk population. Study Design Institutional review board-approved retrospective review of a large, urban population. Methods Data from 875 adult patients treated from January 2008 to December 2013 with the diagnosis of angioedema were obtained using the Clinical Looking Glass utility and review of medical records. Demographic and clinicopathologic risk factors were recorded. The major outcomes evaluated were hospital admission, need for airway intervention, and recurrent episodes of angioedema following the first presentation. Initial treatment strategy and follow-up recommendations were also recorded. Results The most common cause of angioedema was angiotensin converting enzyme inhibitor (ACEi)-induced (496 [56.6%]). Significant risk factors for severe cases of angioedema included older age, Hispanic race, ACEi-induced angioedema type, American Society of Anesthesiologists class III or above, coexistent cardiopulmonary disease, and a positive smoking history. A total of 17.2% of patients experienced recurrent attacks of angioedema; of those patients, 25.9% were still taking an ACEi at subsequent presentation. Risk factors for recurrent episodes included older age, idiopathic angioedema type, and coexistent cardiopulmonary disease. Only 54.1% of patients who experienced ACEi-induced angioedema had electronic medical record documentation of these allergies. Conclusions Knowledge of risk factors for severe and recurrent episodes of angioedema and improved education for both healthcare providers and patients, specifically related to ACEi use and allergy documentation, may significantly decrease the burden and morbidity of angioedema among high risk populations. Level of Evidence 2b. Laryngoscope, 124:2502–2507, 2014Keywords
This publication has 28 references indexed in Scilit:
- ACE Inhibitor–Induced AngioedemaThe Journal of Allergy and Clinical Immunology: In Practice, 2013
- 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaAllergy, Asthma & Clinical Immunology, 2010
- ACE-I induced angioedema: a case report and review of literatureCases Journal, 2009
- Analysis of Recurrent Angiotensin Converting Enzyme Inhibitor-Induced AngioedemaThe Laryngoscope, 2008
- Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency departmentAnnals of Allergy, Asthma & Immunology, 2008
- An evaluation of risk factors for adverse drug events associated with angiotensin‐converting enzyme inhibitorsJournal of Evaluation in Clinical Practice, 2004
- ACE Inhibitor???Induced AngioedemaDrug Safety, 1998
- Increased sensitivity to bradykinin among African AmericansJournal of Allergy and Clinical Immunology, 1996
- Hereditary AngioedemaThe New England Journal of Medicine, 1996
- Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors.BMJ, 1987